pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria
Alexion Europe SAS
Alexion Pharma Germany is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypophosphatasia, Paroxysmal Nocturnal Hemoglobinuria, Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
EU HQ
89 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Employees
- 89
- Programs
- 33
- Drugs
- 40
- Patents
- 0
Ravulizumab
Phase 3 · mab · Atypical Hemolytic Uremic Syndrome (aHUS)
Ravulizumab for Atypical Hemolytic Uremic Syndrome (aHUS) is a Phase 3 program (mab) at Alexion Europe SAS with 2 ClinicalTrials.gov record(s).
Internal code ALXN1210-aHUS-311
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Alexion Europe SAS
- Phase
- Phase 3
- Modality
- mab
- Indication
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Status
- completed
- Trials
- 2